CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: BlueCheap who wrote (519)	11/29/1999 10:56:00 AM
From: Mike McFarland	Read Replies (1) of 675

Two more patents biz.yahoo.com ''Cambridge NeuroScience has an extremely strong proprietary position in the use GGF2 for the treatment of MS and other neurological disorders,'' said Harry Wilcox, President and C.E.O. of Cambridge NeuroScience. ''With 14 patents related to this growth factor and 54 pending, our aggressive patent strategy related to GGF2 continues to build value for our ongoing program with Bayer AG and our shareholders.''

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next